Retatrutide

Description

DESCRIPTION

Retatrutide (LY3437943) is an investigational long‑acting peptide studied as a triple agonist at the GLP‑1, GIP, and glucagon receptors. Its multi‑receptor activity is being explored in metabolic research models focusing on glucose homeostasis, adiposity regulation, energy expenditure, hepatic signaling, and cardiometabolic function. Preclinical and early‑phase studies evaluate its biochemical influence across appetite modulation pathways, insulin sensitivity, and whole‑body energy balance.

LYOPHILIZED PEPTIDES

This peptide is provided in lyophilized powder form to preserve purity, structural stability, and long‑term molecular integrity. No fillers or excipients are used in the freeze‑drying process.

RESEARCH APPLICATIONS

1 — Obesity & Weight‑Regulation Mechanisms

Retatrutide is studied for its multi‑agonist influence on appetite signaling, thermogenic pathways, and body‑weight modulation. Researchers investigate its effects on GLP‑1/GIP synergy and glucagon‑mediated energy expenditure.

(References: Nature—https://www.nature.com/articles/s41591-023-02590-2, PubMed—https://pubmed.ncbi.nlm.nih.gov/37365087/ )

2 — Type 2 Diabetes & Glycemic Research

Preclinical and clinical models assess Retatrutide’s impact on glucose control, insulin signaling, pancreatic islet responsiveness, and glycemic stability. Its multi‑receptor activation offers a broad mechanistic profile for evaluating metabolic flexibility.

(References: ScienceDirect—https://www.sciencedirect.com/science/article/pii/S1550413123002073, PubMed—https://pubmed.ncbi.nlm.nih.gov/37581871/ )

3 — Hepatic & Metabolic‑Liver Function

Studies examine Retatrutide’s influence on hepatic lipid turnover, steatosis models, and glucagon‑regulated liver pathways. Its triple‑agonist nature supports evaluation of liver fat metabolism and metabolic‑health markers.

(References: MDPI—https://www.mdpi.com/1422-0067/24/3/2341, PubMed—https://pubmed.ncbi.nlm.nih.gov/36638174/ )

4 — Cardiometabolic & Body‑Composition Effects

Research explores potential effects on resting‑energy expenditure, lipid markers, inflammation reduction, and cardiometabolic outcomes. Multi‑agonist peptides like Retatrutide allow detailed modeling of systemic metabolic improvements.

(References: Frontiers—https://www.frontiersin.org/articles/10.3389/fendo.2023.1211441/full, PubMed—https://pubmed.ncbi.nlm.nih.gov/36971244/ )

SPECIFICATIONS

Property | Details

Peptide Name | Retatrutide (LY3437943)

Amino Acid Sequence | 39‑amino‑acid synthetic triple‑agonist peptide

CAS Number | 2381089‑83‑2

Molecular Weight | ~4731 Da

Purity | ≥ 99% (HPLC verified)

Form | Lyophilized powder

Appearance | White to off‑white powder

Solubility | Soluble in bacteriostatic/sterile water

Storage | Store dry at −20 °C; protect from light

Usage | Laboratory research only

Research Data & References

– Triple‑agonist metabolic research: https://pubmed.ncbi.nlm.nih.gov/37365087/

– Glycemic and insulin‑signaling studies: https://pubmed.ncbi.nlm.nih.gov/37581871/

– Hepatic metabolic modeling: https://pubmed.ncbi.nlm.nih.gov/36638174/

Disclaimer — Research Use Only

All information presented herein is intended solely for laboratory and educational research. These materials are not approved for human or veterinary use, nor for diagnostic or therapeutic application. Descriptions of biochemical activity are provided for informational context only and must not be interpreted as medical advice. Researchers are expected to handle all compounds in compliance with local regulations and institutional safety standards. EOC Labs supports responsible, ethical, and compliant scientific inquiry.